

Investor Newsletter

Issue 08 2014

 **MicroPort**

The 9th Ice City Cardiovascular Conference Held

On August 1 to August 3, the 9th Ice City Cardiovascular Conference, organized by the 2nd Affiliated Hospital of Harbin Medical University, was held in Harbin. During the conference, Shanghai MicroPort Medical (Group) Co ("MicroPort") held a satellite meeting on Firehawk® case-sharing and clinical result of TARGET serial products on August 2. On August 3, MicroPort organized a discussion on cardiovascular diseases, in which it analyzed different treatment of the disease case by case.

2014 Yangtze River Medical Forum Held

On August 1 to August 3, 2014 Yangtze River Medical Forum was held in Jiangsu Province. About 1,000 surgeons attended the congress. MicroPort participated in the event with a booth. Many surgeons visited our booth and showed interests in our SUPERPATH® as well as neck and knee devices. We believe the forum will help us promote our brand and products in Jiangsu market.



MicroPort Project Awarded Subsidies from National Natural Science Fund



On July 28, MicroPort's project on "the degradation controllability and biological characteristics of magnesium alloy cervical fusion," which is under the cooperation with Shanghai Huashan Hospital, was awarded subsidies from National Natural Science Fund. This is the second national-level project of MicroPort.

Development of Soft Tissue Repairing Products

On July 21, MicroPort Medical Research Department launched a project to develop soft tissue repairing products. The project was awarded funds from Science and Technology Commission of Shanghai Municipality, which would facilitate its development.

Firehawk®
Rapamycin
Target Eluting
Coronary Stent
System

3 MicroPort Attends CHC to Promote Firehawk

MicroPort attended China Heart Congress (CHC) 2014, held from August 7 to August 10 in Beijing, to promote its star product Firehawk® Rapamycin Target Eluting Coronary Stent System.

During this most influential cardiovascular congress in China, MicroPort presented Firehawk®'s safety and efficiency with an eye-catching booth, which features theme posters, amplified Firehawk® model and a seven square-meter LED screen showing introduction video of the product. Meanwhile, MicroPort shared the latest clinical data of Firehawk® in the past three years, which was positively received by participants.

On August 8, MicroPort held a satellite symposium on Firehawk®'s latest development. Several renowned experts, including Professor Runlin Gao of Fuwai Hospital, President of Shanghai Ruijin Hospital Weifeng Shen and Professor Haichang Wang from Xi'an-based Xijing Hospital, were invited to host the symposium. During the event, Professor Zheng Wu of Beijing Anzhen Hospital introduced in depth five features of Firehawk®, while Bo Xu, Director of Intervention Catheter Department with Fuwai Hospital, released the latest Research & Development results of TARGET products to the audience.

"Firehawk® is leading the market in both design concept and clinical results. As the first coronary stent independently designed and developed by a Chinese company, Firehawk® will contribute to the academic advancement in relevant fields," said Professor Gao.

Miami Sales Meeting


From August 20 to August 22, MicroPort Orthopedics Latin America (LatAm) Sales Meeting took place in Miami and brought together more than 50 employees of distributors of the region.

This meeting addressed important topics such as Compliance and Regulatory Affairs. In addition, participants were able to ask questions about the present moment of MicroPort Orthopedics directly to Aurelio Sahagun, the Vice President of MicroPort Orthopedics International and to Ricardo Caruso, Senior Director of MicroPort Orthopedics Latin America.

To reinforce the marketing messages of MicroPort Orthopedics, a training session was conducted with focus on products for the hip - PROFEMUR® family and SUPERPATH® - and for the Knee, highlighting our Medial Pivot philosophy with ADVANCE® and EVOLUTION® products.



Latin America is an important pillar of growth for MicroPort global strategy. In 2014 the company allocated large investments in the region and the goal is to keep pace in 2015.



MicroPort Attends CHINA-HOSPEQ

On August 16, the 23rd China International Medical Equipment Exhibition & Scientific Conference (CHINA-HOSPEQ) was held in Beijing. Deputy General Manager of MicroPort Endovascular (Shanghai) Co delivered a speech on the current and future development of China's endovascular intervention products and joined in discussions with participants. Several renowned doctors were invited to analyze vascular diseases case-by-case.

MicroPort Orthopedics Shanghai Held Academic Symposium

Shanghai MicroPort Orthopedics Co (“MicroPort Orthopedics Shanghai”), a wholly owned subsidiary of MicroPort, held an orthopedic symposium - “Integrity in Motion” - State of the Art in Hip & Knee Arthroplasty on August 23 in Shanghai. The academic event, which attracted more than 200 Chinese and International joint arthroplasty experts, is the first of its kind held by MicroPort Orthopedics Shanghai after the acquisition of OrthoRecon business from Wright Medical Group Inc. (“Wright Medical”) in January 2014.

The symposium featured clinical experiences with the key products offered under the hip and knee reconstruction portfolios of MicroPort, including SUPERPATH® tissue-sparing surgical techniques and ADVANCE® Medial-Pivot Knee, shared by several renowned experts.

Jimmy Chow, Hip and Knee Replacement Surgeon at St. Luke’s Medical Center located in Phoenix of the US, explained in details how revolutionary the SUPERPATH® surgical techniques is, which was positively received by surgeons in attendance. The SUPERPATH® technique is a tissue-sparing procedure which aims to get patients back on their feet within days (possibly hours) instead of weeks or months. With SUPERPATH®, there is no surgical dislocation of the hip. Patients can also have as little as a 3-inch incision. Because of the elimination of damage to these important structures during reconstruction, patients typically have a short hospital stay and a number of patients walk the same day as their surgery.

Such surgical technique is gaining higher market recognition world-wide with the growing demand of joint replacement surgeries. According to survey by World Health Organization, more than 80 percent of people aged above 55 are suffering from joint diseases, mostly hip and knee problems, and a certain percentage of them need joint replacement surgeries to improve their lives.



First Use of SUPERPATH® in East China

MicroPort Orthopedics Shanghai witnessed the first use of its SUPERPATH® surgical techniques in East China, in a hip arthroplasty by Shanghai Huashan Hospital on August 26.

SUPERPATH® technique is a tissue-sparing procedure which offers patients a more rapid return to function, less pain and less blood loss when compared to traditional hip reconstruction surgical techniques. A SUPERPATH® Hip Replacement is designed to precisely reconstruct the hip without cutting critical tendons and stretching or traumatizing muscles that are important to hip function, and with SUPERPATH®, there is no surgical dislocation of the hip. Patients can also have as little as a 3-inch incision. Because of the elimination of damage to these important structures during reconstruction, patients typically have a short hospital stay, and a number of patients walk the same day as their surgery.

In the case by Huashan Hospital, SUPERPATH® is expected to enable the patient, aged above 60 who suffered from fractures of femoral neck, to walk within four days, one week earlier compared to traditional surgical techniques.

"This case represents a good beginning for SUPERPATH® in China," said General Manager of MicroPort Orthopedics Shanghai Shengqiang Wang. "With the growing demand for joint replacement, we believe this revolutionary surgical technique will gain higher recognition among patients and surgeons."



Investor Newsletter

Issue **08** 2014



For more information, please contact:

Hongbin Sun

Chief Financial Officer
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600

Email: ir@microport.com

Xun You

Board Secretary
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600

Email: ir@microport.com